Evert Küppers is an all-rounded executive with over 25 years of operational experience in pharma & biotech with focus on Business & Corporate Development, Fundraising, and R&D Operations. As CEO, he led successfully cross-functional, international Management and R&D teams and closed multiple investment rounds with international, blue chip US/EU investors, as well as, private/public investors. For example, as CEO of Munich-based Pieris Pharmaceuticals (PIRS) he played a pivotal role in its R&D restructuring and subsequently refinancing led by US investor OrbiMed Advisors, which laid eventually the basis for its successful NASDAQ listing. Evert is an educated biomedical scientist (MSc., Leiden University, NL) and obtained an MBA degree from the RSM/Erasmus University, NL.